Baxter International Inc. (BAX)

$39.65

+0.13

(+0.33%)▲

Market is closed - opens 7 PM, 19 Apr 2024

Insights on Baxter International Inc.

  • Increasing Revenue

    Revenue is up for the last 4 quarters, 3.64B → 3.88B (in $), with an average increase of 2.1% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 2.50B → 245.0M (in $), with an average decrease of 90.2% per quarter

  • Vs ISRG

    In the last 1 year, Intuitive Surgical, Inc. has given 39.0% return, outperforming this stock by 46.7%

  • Vs ISRG

    In the last 3 years, Intuitive Surgical, Inc. has given 38.1% return, outperforming this stock by 92.4%

Performance

  • $39.29
    $39.70
    $39.65
    downward going graph

    0.91%

    Downside

    Day's Volatility :1.03%

    Upside

    0.13%

    downward going graph
  • $30.55
    $49.12
    $39.65
    downward going graph

    22.95%

    Downside

    52 Weeks Volatility :37.81%

    Upside

    19.28%

    downward going graph

Returns

PeriodBaxter International Inc.Sector (Health Care)S&P500
3 Months
1.75%
-0.7%
5.0%
6 Months
23.27%
6.6%
16.4%
1 Year
-7.71%
3.7%
20.9%
3 Years
-54.32%
14.0%
20.0%

Highlights

Market Capitalization
20.2B
Book Value
$16.55
Dividend Share
1.16
Dividend Yield
2.93%
Earnings Per Share (EPS)
-0.15
PEG Ratio
1.7
Wall Street Target Price
45.0
Profit Margin
17.93%
Operating Margin TTM
12.07%
Return On Assets TTM
3.34%
Return On Equity TTM
-0.96%
Revenue TTM
14.8B
Revenue Per Share TTM
29.28
Quarterly Revenue Growth YOY
3.6999999999999997%
Gross Profit TTM
6.0B
EBITDA
2.8B
Diluted Eps TTM
-0.15
Quarterly Earnings Growth YOY
0.34
EPS Estimate Current Year
2.9
EPS Estimate Next Year
3.23
EPS Estimate Current Quarter
0.86
EPS Estimate Next Quarter
0.62

Analyst Recommendation

Hold
    40%Buy
    60%Hold
    0
    0%Sell
Based on 20 Wall street analysts offering stock ratings for Baxter International Inc.(by analysts ranked 0 to 5 stars)
Based on 20 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
9
Hold
12
12
13
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 13.49%

Current $39.65
Target $45.00

Company Financials

FY18Y/Y Change
Revenue
11.1B
↑ 5.36%
Net Income
1.6B
↑ 126.5%
Net Profit Margin
14.6%
↑ 7.81%
FY19Y/Y Change
Revenue
11.4B
↑ 2.11%
Net Income
1.0B
↓ 38.36%
Net Profit Margin
8.81%
↓ 5.79%
FY20Y/Y Change
Revenue
11.7B
↑ 2.74%
Net Income
1.1B
↑ 10.09%
Net Profit Margin
9.44%
↑ 0.63%
FY21Y/Y Change
Revenue
12.8B
↑ 9.52%
Net Income
1.3B
↑ 16.52%
Net Profit Margin
10.04%
↑ 0.6%
FY22Y/Y Change
Revenue
15.1B
↑ 18.22%
Net Income
-2.4B
↓ 288.55%
Net Profit Margin
-16.02%
↓ 26.06%
FY23Y/Y Change
Revenue
14.8B
↓ 1.99%
Net Income
2.7B
↓ 209.71%
Net Profit Margin
17.93%
↑ 33.95%
Q3 FY22Q/Q Change
Revenue
3.8B
↑ 0.72%
Net Income
-2.9B
↓ 1264.29%
Net Profit Margin
-77.76%
↓ 84.49%
Q4 FY22Q/Q Change
Revenue
3.9B
↑ 3.02%
Net Income
181.0M
↓ 106.17%
Net Profit Margin
4.66%
↑ 82.42%
Q1 FY23Q/Q Change
Revenue
3.6B
↓ 6.12%
Net Income
44.0M
↓ 75.69%
Net Profit Margin
1.21%
↓ 3.45%
Q2 FY23Q/Q Change
Revenue
3.7B
↑ 1.59%
Net Income
-141.0M
↓ 420.45%
Net Profit Margin
-3.8%
↓ 5.01%
Q3 FY23Q/Q Change
Revenue
3.7B
↑ 0.03%
Net Income
2.5B
↓ 1878.72%
Net Profit Margin
67.64%
↑ 71.44%
Q4 FY23Q/Q Change
Revenue
3.9B
↑ 4.77%
Net Income
245.0M
↓ 90.23%
Net Profit Margin
6.31%
↓ 61.33%
FY18Y/Y Change
Total Assets
15.6B
↓ 8.59%
Total Liabilities
7.8B
↓ 2.13%
FY19Y/Y Change
Total Assets
18.2B
↑ 16.32%
Total Liabilities
10.3B
↑ 31.39%
FY20Y/Y Change
Total Assets
20.0B
↑ 10.04%
Total Liabilities
11.3B
↑ 9.84%
FY21Y/Y Change
Total Assets
33.5B
↑ 67.45%
Total Liabilities
24.4B
↑ 116.06%
FY22Y/Y Change
Total Assets
28.3B
↓ 15.61%
Total Liabilities
22.4B
↓ 8.23%
FY23Y/Y Change
Total Assets
28.3B
↓ 0.04%
Total Liabilities
19.8B
↓ 11.54%
Q3 FY22Q/Q Change
Total Assets
28.0B
↓ 12.15%
Total Liabilities
22.4B
↓ 2.36%
Q4 FY22Q/Q Change
Total Assets
28.3B
↑ 1.15%
Total Liabilities
22.4B
↑ 0.03%
Q1 FY23Q/Q Change
Total Assets
28.3B
↑ 0.01%
Total Liabilities
22.4B
↓ 0.19%
Q2 FY23Q/Q Change
Total Assets
27.9B
↓ 1.44%
Total Liabilities
22.3B
↓ 0.43%
Q3 FY23Q/Q Change
Total Assets
30.7B
↑ 9.94%
Total Liabilities
22.5B
↑ 1.06%
Q4 FY23Q/Q Change
Total Assets
28.3B
↓ 7.76%
Total Liabilities
19.8B
↓ 11.93%
FY18Y/Y Change
Operating Cash Flow
2.1B
↑ 14.1%
Investing Cash Flow
-938.0M
↓ 28.4%
Financing Cash Flow
-2.6B
↓ 4367.21%
FY19Y/Y Change
Operating Cash Flow
2.1B
↑ 0.38%
Investing Cash Flow
-1.1B
↑ 17.27%
Financing Cash Flow
498.0M
↓ 119.13%
FY20Y/Y Change
Operating Cash Flow
1.9B
↓ 11.22%
Investing Cash Flow
-1.2B
↑ 7.18%
Financing Cash Flow
-345.0M
↓ 169.28%
FY21Y/Y Change
Operating Cash Flow
2.2B
↑ 18.95%
Investing Cash Flow
-11.2B
↑ 849.96%
Financing Cash Flow
8.2B
↓ 2489.86%
FY22Y/Y Change
Operating Cash Flow
1.2B
↓ 45.5%
Investing Cash Flow
-931.0M
↓ 91.69%
Financing Cash Flow
-1.4B
↓ 117.44%
Q3 FY22Q/Q Change
Operating Cash Flow
290.0M
↑ 5.84%
Investing Cash Flow
-184.0M
↓ 1.6%
Financing Cash Flow
-302.0M
↓ 35.61%
Q4 FY22Q/Q Change
Operating Cash Flow
439.0M
↑ 51.38%
Investing Cash Flow
-256.0M
↑ 39.13%
Financing Cash Flow
-119.0M
↓ 60.6%
Q1 FY23Q/Q Change
Operating Cash Flow
479.0M
↑ 9.11%
Investing Cash Flow
-170.0M
↓ 33.59%
Financing Cash Flow
-372.0M
↑ 212.61%
Q2 FY23Q/Q Change
Operating Cash Flow
351.0M
↓ 26.72%
Investing Cash Flow
-173.0M
↑ 1.76%
Financing Cash Flow
-120.0M
↓ 67.74%
Q3 FY23Q/Q Change
Operating Cash Flow
365.0M
↑ 3.99%
Investing Cash Flow
3.4B
↓ 2090.17%
Financing Cash Flow
-62.0M
↓ 48.33%

Technicals Summary

Sell

Neutral

Buy

Baxter International Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Baxter International Inc.
Baxter International Inc.
-4.86%
23.27%
-7.71%
-54.32%
-46.83%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
-4.7%
35.81%
38.95%
38.38%
112.57%
Resmed Inc.
Resmed Inc.
-8.97%
22.05%
-22.01%
-15.48%
75.2%
Becton, Dickinson And Company
Becton, Dickinson And Company
-2.32%
-10.48%
-8.43%
-10.33%
1.9%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
-4.64%
0.62%
4.23%
19.12%
238.38%
Alcon Ag
Alcon Ag
-6.1%
7.94%
11.1%
7.08%
42.78%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Baxter International Inc.
Baxter International Inc.
85.61
NA
1.7
2.9
-0.01
0.03
0.03
16.55
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
75.26
75.26
7.13
6.25
0.15
0.08
NA
37.77
Resmed Inc.
Resmed Inc.
30.61
30.61
1.75
7.41
0.22
0.11
0.01
30.47
Becton, Dickinson And Company
Becton, Dickinson And Company
52.86
52.86
1.34
12.95
0.05
0.03
0.02
87.68
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
48.1
48.1
6.72
7.62
0.21
0.12
0.0
39.2
Alcon Ag
Alcon Ag
40.62
40.62
4.59
3.06
0.05
0.02
0.0
41.81
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Baxter International Inc.
Baxter International Inc.
Hold
$20.2B
-46.83%
85.61
17.93%
Intuitive Surgical, Inc.
Intuitive Surgical, Inc.
Buy
$134.2B
112.57%
75.26
25.24%
Resmed Inc.
Resmed Inc.
Buy
$27.2B
75.2%
30.61
19.77%
Becton, Dickinson And Company
Becton, Dickinson And Company
Buy
$67.8B
1.9%
52.86
6.44%
West Pharmaceutical Services Inc
West Pharmaceutical Services Inc
Buy
$27.8B
238.38%
48.1
20.12%
Alcon Ag
Alcon Ag
Buy
$39.5B
42.78%
40.62
10.3%

Institutional Holdings

  • Vanguard Group Inc

    11.81%

  • BlackRock Inc

    11.72%

  • Dodge & Cox

    5.38%

  • Pzena Investment Management, LLC

    4.76%

  • State Street Corporation

    4.19%

  • T. Rowe Price Associates, Inc.

    3.22%

Corporate Announcements

  • Baxter International Inc. Dividends March,2024

    In the quarter ending March,2024. Baxter International Inc. has declared dividend of $0.29

    Read More

Company Information

baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile iv solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. the company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

Organization
Baxter International Inc.
Employees
60000
CEO
Mr. Jose E. Almeida
Industry
Health Technology

Discover More

FAQs